

Eric X Chen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4589028/eric-x-chen-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

555
citations

12
h-index

23
g-index

33
ext. papers

734
ext. citations

4.2
avg, IF

3
L-index

#	Paper	IF	Citations
31	Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, 193-202	7.3	1
30	Anal Adenocarcinoma: A Rare Entity in Need of Multidisciplinary Management.. <i>Diseases of the Colon and Rectum</i> , 2022 , 65, 189-197	3.1	
29	Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer. <i>Cancer Research Communications</i> , 2022 , 2, 293-306		0
28	Combined 18F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer.. <i>Clinical Nuclear Medicine</i> , 2022 ,	1.7	2
27	Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma. <i>Cancer Medicine</i> , 2021 , 10, 199-207	4.8	3
26	Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer. <i>Oncology</i> , 2021 , 99, 49-56	3.6	5
25	Influence of sarcopenia, clinical data, and 2-[F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1	8.8	0
24	Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer.. <i>Cancer Medicine</i> , 2021 ,	4.8	1
23	Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2020 , 11, 356-365	2.8	1
22	Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma. <i>Cancer Medicine</i> , 2020 , 9, 3023-3032	4.8	3
21	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 539-545	4.9	3
20	Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 1195-1200	3.5	3
19	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019 , 24, 1188-1194	5.7	17
18	Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2019 , 50, 801-807	1.6	5
17	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019 , 118, 112-120	7.5	5
16	A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity. <i>Journal of Oncology Pharmacy Practice</i> , 2019 , 25, 875-883	1.7	9
15	Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort. <i>Head and Neck</i> , 2018 , 40, 2029-2042	4.2	14

14	A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 231-239.e7	3.8	27
13	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 73-79	3.8	16
12	The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. <i>Oncotarget</i> , 2018 , 9, 20439-20450	3.3	9
11	Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. <i>Cancer Medicine</i> , 2018 , 7, 5478-5487	4.8	12
10	Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018 , 144, 71-79	3.9	22
9	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 994-1002	4	1
8	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016 , 8, 109	14.4	149
7	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , 2016 , 34, 575-83	4.3	6
6	A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. <i>Investigational New Drugs</i> , 2016 , 34, 450-7	4.3	27
5	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 67, 174-182	7.5	46
4	Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma. <i>Oncotarget</i> , 2015 , 6, 4537-50	3.3	40
3	Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 587-94	4	61
2	Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 590-8	9.7	67
1	Standard of Care Evaluation of Venous Thromboembolism Prophylaxis in Selected Solid Tumour Patients at a Tertiary Cancer Care Teaching Hospital.. <i>Blood</i> , 2004 , 104, 4066-4066	2.2	